Scarica l'app Stockscreener
2.26
0.88%
-0.02
Pre-mercato:
2.32
0.06
+2.65%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Precedente Chiudi:
$2.28
Aprire:
$2.28
Volume 24 ore:
7.52M
Relative Volume:
0.86
Capitalizzazione di mercato:
$2.14B
Reddito:
$1.31M
Utile/perdita netta:
$-597.65M
Rapporto P/E:
-2.3299
EPS:
-0.97
Flusso di cassa netto:
$-425.62M
1 W Prestazione:
-19.86%
1M Prestazione:
-17.82%
6M Prestazione:
-37.91%
1 anno Prestazione:
-43.07%
Intervallo 1D:
$2.17
$2.3221
Intervallo di 1 settimana:
$2.17
$2.79
Portata 52W:
$1.83
$7.48
Immunitybio Inc Stock (IBRX) Company Profile
Nome
Immunitybio Inc
Settore
Industria
Telefono
(844) 696-5235
Indirizzo
3530 JOHN HOPKINS COURT, SAN DIEGO
Confronta IBRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.26 | 2.30B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.36 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.01 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.31 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.97 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.33 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | BTIG Research | Buy |
| 2023-05-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Iniziato | Jefferies | Buy |
Immunitybio Inc Borsa (IBRX) Ultime notizie
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates - MSN
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID - BioSpace
ImmunityBio Settled With Investors Over FDA Rejection Drama— How to Claim Your Share - TradingView
Q2 2025 CRO Activity and Intel Report Featuring ICON, AstraZeneca, Akesobio, CSPPC Pharmaceutical, ImmunityBio, BoryungResearchAndMarkets.com - FinancialContent
ImmunityBio Launching New Phase 2 Trial of Anktiva to Treat Long COVID - MarketScreener
ImmunityBio launches phase 2 study of ANKTIVA for long COVID - Investing.com
ImmunityBio Inc. Stock Flags Risk Zone in Volatility IndexJuly 2025 EndofMonth & Entry Point Confirmation Signals - sundaytimes.kr
ImmunityBio Wins U.K. Approval - Los Angeles Business Journal
Fibonacci Retracement Aligns with Support in ImmunityBio Inc.July 2025 News Drivers & Fast Momentum Entry Tips - newsimpact.co.kr
Published on: 2025-08-17 09:14:13 - metal.it
Heatmap Data Shows High Activity in ImmunityBio Inc. Sector2025 Earnings Surprises & Fast Exit/Entry Strategy Plans - sundaytimes.kr
Is ImmunityBio Inc.’s growth already priced inMarket Performance Recap & AI Powered Market Trend Analysis - thegnnews.com
Is ImmunityBio Inc. a speculative investmentTrade Volume Report & Fast Gain Swing Alerts - sundaytimes.kr
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results - MSN
Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter - Oncodaily
ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView
Is ImmunityBio Inc. stock a value trap2025 Valuation Update & Expert Verified Stock Movement Alerts - thegnnews.com
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates - ADVFN Brasil
RSI + MACD Show Convergence for ImmunityBio Inc.2025 Price Targets & Growth Focused Stock Pick Reports - sundaytimes.kr
ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment - TipRanks
ImmunityBio shares fall 1.95% intraday after Q2 net loss and revenue rise. - AInvest
Why ImmunityBio (IBRX) Is Up 18.5% After Early VA Uptake of ANKTIVA and Improving Financials - simplywall.st
ImmunityBio higher after early-stage trial results for cell therapy in lymphoma - MSN
ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy - BioSpace
ImmunityBio stock surges on promising trial results for lymphoma treatment, analysts forecast significant upside potential. - AInvest
ImmunityBio Shares Rise After 'Promising' Results From Lymphoma Treatment - MarketScreener
Hillenbrand, ImmunityBio, V2X - TradingView
ImmunityBio Surges 15% on Groundbreaking Cancer Trial Results: A New Era for NK Cell Therapy? - AInvest
ImmunityBio announces early findings from QUILT-106 trial - TipRanks
ImmunityBio’s Q2 Earnings Surge Due to ANKTIVA Success - StocksToTrade
Lumentum Holdings, ImmunityBio, V2X - TradingView
ImmunityBio Stock Surges on Robust Q2 Earnings Report - timothysykes.com
Immunitybio stock soars after promising cancer therapy trial results By Investing.com - Investing.com Canada
ImmunityBio's NK cell therapy shows promise in lymphoma trial. - AInvest
ImmunityBio up on trial data for cell therapy (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio rises after early data for blood cancer cell therapy - TradingView
ImmunityBio’s Stock Surges on Promising Trial Results - TipRanks
CD19 CAR-NK therapy shows complete responses in late-stage lymphoma - Investing.com Canada
VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - Vax-Before-Travel
ImmunityBio shares rise 1.21% premarket after ANKTIVA treatment approval for bladder cancer. - AInvest
ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - MarketScreener
ImmunityBio’s Shareholder Settlement Gains Preliminary Approval - The Globe and Mail
ImmunityBio Shareholder Settlement Gains Preliminary Approval, Boosting Company's Future Prospects - AInvest
Investors Can Still File Late Claims in ImmunityBio Settlement — Here’s How to Get Your Share - TradingView
Why Investors Shouldn't Be Surprised By ImmunityBio, Inc.'s (NASDAQ:IBRX) P/S - 富途牛牛
Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Q2 2025 Revenue Up 5% YoY to $1,241mln; Raises FY23 Guidance, Innovation Target. - AInvest
ImmunityBio Q2 Earnings Show 60% Revenue Growth, $153.7 Million in Cash, and Strong Sales Momentum. - AInvest
ImmunityBio's ANKTIVA Receives Buy Rating Amid Expanding Oncology Potential and Market Growth - AInvest
ImmunityBio Reports Q2 Earnings with 60% Revenue Increase, $43M in Sales, and 246% Unit Growth - AInvest
ImmunityBio 2025 Q2 Earnings Sustained Losses Amid Strong Revenue Surge - AInvest
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunitybio Inc Azioni (IBRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SOON-SHIONG PATRICK | See remarks |
Feb 22 '25 |
Option Exercise |
0.00 |
114,329 |
0 |
29,588,261 |
| Sachs David C. | Chief Financial Officer |
Feb 22 '25 |
Option Exercise |
0.00 |
40,650 |
0 |
241,480 |
| Adcock Richard | CEO & President |
Feb 22 '25 |
Option Exercise |
0.00 |
152,439 |
0 |
412,585 |
| Simon Barry J. | Director |
Feb 22 '25 |
Option Exercise |
0.00 |
15,243 |
0 |
3,249,024 |
| Simon Barry J. | Director |
Jan 22 '25 |
Option Exercise |
2.00 |
110,020 |
219,864 |
3,233,781 |
| Adcock Richard | CEO & President |
Dec 31 '24 |
Option Exercise |
0.00 |
34,483 |
0 |
277,621 |
| Sachs David C. | Chief Financial Officer |
Dec 31 '24 |
Option Exercise |
0.00 |
30,397 |
0 |
216,235 |
| LAUER REGAN J | Chief Accounting Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
21,031 |
0 |
115,365 |
2.44%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):